Natera, one of the players in pre-natal genetic testing, will be launching its Non-Invasive Prenatal Test Panorama on 1st March. Natera’s Panorama can detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and sex chromosome abnormalities like monosomy X (Turner’s syndrome).
Like other pre-natal testing companies, Natera’s test uses fetal cell-free DNA from pregnant woman can detect these abnormalities as early as nine weeks gestation. Unlike other Non-invasive pre-natal tests, Natera’s test is SNP based. Natera analyzes over 19,000 SNPs using NATUS [Next-generation Aneuploidy Testing Using SNPs] algorithm, its proprietary informatics solution.
Just recently, Natera presented data from a clinical trial analyzing 764 maternal blood samples, Natera’s Panorama had a sensitivity of greater than 99% for detecting chromosomal abnormalities like Down syndrome,Edwards syndrome, Patau syndrome and 92% when detecting monosomy X (Turner’s syndrome). And the test also had a specificity of 100% with no false positives for all the syndromes tested.
In the press release announcing the launch of Panorma, Matthew Rabinowitz, Ph.D., chief executive officer of Natera, said
Every set of data we have received from clinical studies of Panorama reinforce our long-held belief that this test can offer patients the most reliable information consistently across multiple chromosomal abnormalities.
Following a successful soft launch in late 2012, we aretaking the final steps for our global launch of this test. Panorama uniquely targets, in a single reaction, 19,500 SNPs (single nucleotide polymorphisms), which are the most informative pieces of an individual’s DNA and we look forward to advancing this technology and improving the care of pregnancies globally.
Just yesterday Natera announced that, it has teamed up with Bio-Reference Laboratories to commercialize its test Panorama. Earlier, Natera also announced that Quest Diagnostics will provide nationwide access to Panorama.